Topics The "Regular Meeting with the French Association of the Pharmaceutical Industry (Leem)" was held
As part of its activities to cooperate with governments and pharmaceutical organizations in Europe and the United States to resolve international issues, the European & American Subcommittee of the JPMA International Affairs Committee holds regular meetings with the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Association of the British Pharmaceutical Industry (ABPI), the French Pharmaceutical Manufacturers Association (Leem), and the German R&D-based Pharmaceutical Manufacturers' Association (vfa) every year. On November 9, 2023, the regular meeting with Leem was held in a hybrid face-to-face and online format, and a lively exchange of views took place.
The venue
Opening Remarks
General Manager, Mr. Leem Philippe Lamoureux
At the outset, Mr. Philippe Lamoureux, Chairman of Leem, delivered remarks in which he expressed his gratitude for his work with the JPMA to date, as he prepares to step down as Leem Chairman at the end of 2023, and emphasized the importance of continuing to maintain and expand exchanges between Japan and France.Sachiko Nakagawa, Executive Director of the JPMA, described Mr. Lamoureux as a valued individual who had strengthened the ties between Leem and the JPMA, and expressed her gratitude while reflecting on their shared experiences.
Current context in France and price cuts for pharmaceutical area
Mr. Leem Eric Baseilhac
He reviewed the current situation caused by the long-standing policy of drug price suppression in France, and introduced the social security financing bill for 2024. As a result of the negotiations, both price reductions and reimbursements were spared in 2024, but only one-third of the drugs approved in the EU are reimbursed in France within three years, a situation similar to Japan in that the drug lag/loss is becoming more serious. Leem is proposing a system to optimize the excessive prescribing of drugs as part of measures to curb medical costs.
Price & Reimbursement
Mr. Leem Laurent Petit
The main focus was on the Early Access system introduced in France in FY2021, with an explanation of the details of the system, its operational status, and issues. In the discussion, opinions were exchanged on the overall access to medicines in Japan and France, and Mr. Leem responded to the operation status of the system and issues for venture companies in France.
Current Status Over the NHI Drug Pricing System in Japan
Mr. Hiroki Iida, Member, JPMA Industrial Policy Committee, Industrial Promotion Subcommittee
The current situation and recognition of issues surrounding the pharmaceutical industry in Japan, the "Kotta Policy 2023" and its impact on the pharmaceutical industry, and discussions at the Central Social Insurance Medical Council (Chuikyo) regarding reform of the NHI drug price system in FY2024 were introduced. During the discussion, a lively Q&A session focused on topics common to both countries, such as the aging of the population and social security costs, and challenges in procuring APIs.
Stable supply of medicinal product
Mr. Leem Céline Kauv
The current situation and background of the drug supply shortage in France and the outline of the roadmap for stable supply from 2023 to 2025 were introduced. The main points of the roadmap were the establishment of a list of critical medicines, support for domestic production of some critical medicines, and the importance of EU-wide efforts rather than on a country-by-country basis.
Drug shortages in Japan
Mr. Toyohiko Honda, Stability Assurance Committee, Japan Federation of Pharmaceutical Manufacturers' Associations
He explained the environment surrounding the pharmaceutical industry in Japan and the causes of supply shortages in Japan, including increased demand for pharmaceuticals, product quality issues, API supply issues, and structural problems in the generic drug industry. During the Q&A session, it became clear that some products in France had had their drug prices raised.
Patient engagement
Ms. Leem Rebecca Ammar
Chairperson, Patient Cooperation Committee, JPMA
For the first time, a discussion was held with Leem on the topic of Patient Engagement. In this session, both Leem and JPMA introduced the committee's position and objectives related to this topic, especially how to promote patient engagement in the healthcare system and drug development, along with specific initiatives. Both sides expressed their sympathy for the importance of dialogue between JPMA and patient groups, as well as other stakeholders, to deepen mutual understanding and work together to solve common problems.
Patient engagement
Shinichi Miura, Chairperson, Europe and North America Subcommittee, International Affairs Committee , JPMA
Laurence Peyraut, General Manager, Leem
Shinichi Miura, Chairperson of the Europe and America Subcommittee of the JPMA International Affairs Committee, remarked, “As matters of mutual interest to Japan and France, we were able to exchange valuable information, including the latest developments in both countries. In particular, reducing drug costs is not only a challenge faced by each country but also a shared issue that we must address together as we pursue sustainable drug innovation for the benefit of patients.He concluded by saying, “We hope to continue fostering regular communication between our organizations.” Ms. Laurence Peyraut of Leem stated, “Like my predecessor, Mr. Lamoureux, I also intend to place great importance on Japan-France exchanges. Since 2024 is the year the Paris Olympics will be held, I would very much like to invite everyone to Paris.”
This bilateral meeting was also a very fruitful one, as both sides were able to deepen their mutual understanding, and there was a lively exchange of opinions during each session.
Group photo
( Masahiro Mizobuchi, Leader, France Team, Europe Group, Europe and North America Subcommittee, International Affairs Committee)